Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain

Pediatric Infectious Disease Journal

Volumn 26, Issue 8, 2007, Pages 667-671

  Benito Fernández, Javier ^a   Raso, Santiago Mintegi ^a   Pocheville Gurutzeta, Itziar ^a   SánchEzetxaniz, Jesús ^a   Azcunaga Santibañez, Beatriz ^a   Capapé Zache, Susana ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Febrile infants; Pneumococcal bacteremia; Pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCAL CONJUGATE VACCINE 7; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRESCHOOL CHILD; PREVENTION AND CONTROL; PRIORITY JOURNAL; PUBLIC HEALTH; PYREXIA IDIOPATHICA; SEROTYPE; SPAIN; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

BACTEREMIA; CHILD, PRESCHOOL; FEMALE; FEVER OF UNKNOWN ORIGIN; HUMANS; INCIDENCE; INFANT; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RETROSPECTIVE STUDIES; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 34548722242     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e3180f610b3     Document Type: Article

References (24)

1. Mintegi Raso S, Benito Fernandez J, Garcia Gonzalez S, Corrales Fernandez A, Bartolome Albistegui MJ, Trebolazabala Quirante N. Patient demand and management in a hospital pediatric emergency setting. An Pediatr (Barc). 2004;61:156-161.
2. Mintegi Raso S, Gonzalez Balenciaga M, Perez Fernandez A, Pijoan Zubizarreta JI, Capape Zache S, Benito Fernandez J. Infants aged 3-24 months with fever without source in the emergency room: characteristics, management and outcome. An Pediatr (Barc). 2005;62:522-528.
3. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2000;49(RR-9):1-35.
4. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
5. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine. A study from a children's hospital emergency department and Urgent care center. Arch Pediatr Adolesc Med. 2004;158:671-675.
6. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
7. Whitney CG, Farley MM, Hadler J, et al. Active bacterial core surveillance of the emerging infections program network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003 1;348:1737-1746.
8. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am. 1999;46:1073-1109.
9. Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Pediatrics. 1993;92:1-12.
10. Mintegi S, Benito J, González M, Astobiza E, Sánchez J, Santiago M. Impact of the pneumococcal conjugate vaccine in the management of highly febrile children aged 6 to 24 months in an emergency department. Pediatr Emerg Care. 2006;22:566-569.
11. Hausdorff WP. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur J Pediatr. 2002;161(suppl 2):135-139.
12. Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology of outpatient bacteremia in 3- to-36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2006;25:293-300.
13. Poehling KA, Lafleur BJ, Szilagyi PG, et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics. 2004;114:755-761.
14. Von Kries R, Hermann M, Al Lahham A, Siedler A, Reinert RR. Will the 7-valent pneumococcal vaccine have a similar impact on all invasive pneumococcal infections in children in Germany as in the Kaiser Permanente Trial. Eur J Pediatr. 2002;161(suppl 1):140-143.
15. Ispahani P, Slack RC, Donald FE, Weston VC, Rutter N. Twenty year surveillance of invasive pneumococcal diseases in Nottingham: serogroups responsible and implications for immunization. Arch Dis Child. 2004;89:757-762.
16. Kalkoft ZN, Konradsen HB. Epidemiology of invasive pneomococcal infections in children aged 0-6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr Suppl. 2000;89:3-10.
17. Iglesias Sánchez L, Perez-Yarza EG, Garcia-Aranzana JM, Valiente-Mendez A, Perez-Trallero E. Epidemiology of invasive pneumococcal disease in children in Gipuzkoa (Spain) from 1981 to 2001. An Esp Pediatr. 2002;57:401-407.
18. Bernaola E, de Arístegui J, Herranz M, García C, Fernández C. Study of the incidence of invasive pneumococcal disease in neonates and children aged less than 5 years in the Basque country and Navarre (Spain). An Esp Pediatr. 2002;57:301-309.
19. Pineda V, Fontanals D, Larramona H, Domingo M, Anton J, Segura F. Epidemiology of invasive Streptococcus pneumoniae infections in children in an area of Barcelona, Spain. Acta Paediatr. 2002;91:1251-1256.
20. Kapplan SL, Mason EO, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-449.
21. Alpern ER, Alessandrini EA, McGowan KL, Bell LM, Shaw KN. Serotupe prevalence of occult pneumococcal bacteremia. Pediatrics. 2001;108:E23.
22. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease 2 among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-1674.
23. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine. Evidence from the first 5 years of use in the united states incorporating herd effects. Pediatr Infect Dis J. 2006;25:494-501.
24. Moore PR, Pilishvili TG, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae 19A from children in the United States. J Infect Dis. 2005;192:1988-1995.